Abstract
Purpose
Systemic immune-inflammation index (SII) has been demonstrated to be closely associated with prognosis of a series of solid tumors. However, its role in small cell lung cancer (SCLC) remains poorly understood. The present study aims to evaluate the prognostic significance of pretreatment SII in SCLC treated with etoposide and platinum-based chemotherapy.
Methods
Sixty hundred and fifty-three newly diagnosed SCLC patients were enrolled. The optimal cut-off values for SII and LDH (lactate dehydrogenase) were obtained by a receiver operating characteristic (ROC) curve analysis. Overall survival (OS) was assessed by univariate and multivariate analyses.
Results
The optimal cut-off values of pretreatment SII and LDH were 748.51 × 109/L and 188.5 U/L, respectively. High pretreatment SII was significantly associated with advanced tumor stage (limited disease, LD vs. extensive disease, ED; 26.3% vs 46.5%; p < 0.001). On univariate analysis, age < 65 years, female, non-smoker, limited disease, SII < 748.51 × 109/L, LDH < 188.5 U/L, distant metastasis numbers < 2, chemotherapy + radiotherapy, and chemotherapy + surgery were closely correlated with a prolonged OS (p < 0.05). The median OS for patients in high SII group was 12.0 months, compared with that of 17.0 months for patients in low SII group. Multivariate analysis showed smoking history (p = 0.014), tumor stage (p < 0.001), pretreatment SII (p < 0.001), LDH (p = 0.002), distant metastasis numbers (p = 0.006), and chemotherapy + radiotherapy (p < 0.001) were independent prognostic factors of OS. Furthermore, SII remained prognostic significance for SCLC stratified by variable subgroups analysis.
Conclusion
Pretreatment SII represents a powerful prognostic biomarker for SCLC patients treated with etoposide and platinum-based chemotherapy. It is significant for treatment strategy making in clinics.
Similar content being viewed by others
References
Gazdar AF, Bunn PA, Minna JD (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17(12):725–737
Rudin CM, Poirier JT (2017) Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nat Rev Clin Oncol 14(2):75–76
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
Gao Y, Zhang H, Li Y, Wang D, Ma Y, Chen Q (2018) Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. Clin Chim Acta 484:272–277
Tong YS, Tan J, Zhou XL, Song YQ, Song YJ (2017) Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med 15(1):221
Chen L, Yan Y, Zhu L, Cong X, Li S, Song S et al (2017) Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manage Res 9:849–867
Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q (2015) Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 236(4):297–304
Tomita M, Ayabe T, Maeda R, Nakamura K (2018) Systemic immune-inflammation index predicts survival of patients after curative resection for non-small cell lung cancer. In Vivo 32(3):663–667
Tomita M, Ayabe T, Maeda R, Nakamura K (2018) Comparison of inflammation-based prognostic scores in patients undergoing curative resection for non-small cell lung cancer. World J Oncol 9(3):85–90
Wang D, Guo D, Shi F, Zhu Y, Li A, Kong L et al (2019) The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer. Future Oncol 15(29):3367–3379
Wang X, Jiang R, Li K (2014) Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys 69(3):633–640
Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE et al (2016) Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer 122(1):50–60
Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9(2):237–249
Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW et al (2018) Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PLoS ONE 13(7):e0200341
Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5):576–590
Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE (2014) Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol 229(8):1005–1015
Jurasz P, AlonsoEscolano D, Radomski MW (2004) Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143(7):819–826
Cao S, Jin S, Shen J, Cao J, Zhang H, Meng Q et al (2017) Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients. Oncotarget 8(5):8657–8669
Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6(4):283–287
Shoji F, Morodomi Y, Akamine T, Takamori S, Katsura M, Takada K et al (2016) Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer. Lung Cancer 98:15–21
Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2(11):850–861
Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239–252
Jin S, Cao S, Xu S, Wang C, Meng Q, Yu Y (2018) Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy. Clin Respir J 12(9):2433–2440
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31(7):860–867
Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA et al (2011) Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res 171(1):1–5
Fu Y, Chen SW, Chen SQ, Ou-Yang D, Liu WW, Song M et al (2016) A preoperative nutritional index for predicting cancer-specific and overall survival in chinese patients with laryngeal cancer: a retrospective study. Medicine 95(11):e2962
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Can Res 58(16):3491–3494
Bernhardt D, Aufderstrasse S, Konig L, Adeberg S, Bozorgmehr F, Christopoulos P et al (2018) Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Manage Res 10:6563–6569
Wei XL, Zhang DS, He MM, Jin Y, Wang DS, Zhou YX et al (2016) The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumour Biol 37(2):1879–1887
Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 379(23):2220–2229
Acknowledgements
This work was funded by Doctor’s Foundation of Linyi People’s Hospital (No 803) and National Natural Scientific Foundation of China (Grant No. 81673007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wang, C., Jin, S., Xu, S. et al. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy. Lung 198, 405–414 (2020). https://doi.org/10.1007/s00408-020-00333-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-020-00333-6